(Received for publication, March 21, 1996, and in revised form, December 5, 1996)
From the Department of Biochemistry, University of Western Ontario, London, Ontario N6A 5C1, Canada
NGG1p/ADA3p and ADA2p are dual function regulators that stimulate or inhibit a set of yeast transcriptional activator proteins. In vitro, NGG1p and ADA2p associate in a complex that also contains GCN5p (Horiuchi, J., Silverman, N., Marcus, G. A., and Guarente, L. (1995) Mol. Cell. Biol. 15, 1203-1209). We have found that NGG1p and ADA2p are coimmunoprecipitated from yeast whole cell extracts. In fact, <2% of cellular ADA2p was not associated with NGG1p. Also in agreement with their association in vivo, the stability of ADA2p and NGG1p depended on the presence of each other. In addition, three NGG1p- and ADA2p-containing peak fractions were resolved by Q-Sepharose Fast Flow ion-exchange chromatography of whole cell extract. The presence of another high molecular mass complex was supported by the separation of one of the NGG1p- and ADA2p-containing peak fractions by gel-filtration chromatography. Together, the combination of ion-exchange and gel-filtration chromatography suggests a total of four complexes, two with sizes of >2 MDa and single complexes of ~900 and 200 kDa. At least one of these complexes was found to associate with the TATA-binding protein (TBP) since TBP was present in immunoprecipitates with NGG1p. The association of TBP with the ADA proteins required amino acids 274-307 of NGG1p, a region of NGG1p required for activity. This supports a role for NGG1p in the interaction with TBP and suggests that the interaction with TBP is functionally relevant.
Activated transcription by RNA polymerase II requires the action of the basal transcriptional machinery, sequence-specific activator proteins, and coactivator or mediator proteins (1). Coactivators positively influence activator function either by providing a regulatory interface between the basal machinery and the activator protein or by enabling these components to contend with a DNA template in the form of chromatin. Coactivators have generally been found as components of regulatory complexes. The TBP1·TBP-associated factor complex, the RNA polymerase II holoenzyme complex, and the Swi·Snf complex represent principal examples (reviewed in Refs. 2-4). The mechanisms and component structure of these complexes may overlap as suggested by the finding of Swi/Snf components (5) within the RNA polymerase II holoenzyme (6), the TBP-associated factor complex, and transcription factor IIF (7).
Probably through related mechanisms, coactivator complexes can also be involved in repression. We initially discovered NGG1 based on its requirement for full inhibition of the GAL4 activator protein in glucose media (8). NGG1p likely acts as a more general repressor because transcriptional activation by the carboxyl-terminal activation domain of PDR1p is enhanced in a ngg1 background (9). Guarente and co-workers (10) independently isolated NGG1/ADA3 based on suppression of the toxicity of overexpression of VP16 in yeast. Mutations within four ADA genes, ADA2, NGG1/ADA3, GCN5/ADA4, and ADA5, suppress the toxicity of VP16 by inhibiting its ability to activate transcription (11, 12). These genes are also required for transactivation by GCN4p (11-13); in fact, GCN5p had been identified because it is required for maximal activation by GCN4p (14). Genetic and in vitro biochemical evidence suggests that the ADA proteins likely act in a complex that contains at least ADA2p, NGG1p, GCN5p, and ADA5p (10-13, 15-18). Direct interaction in vitro has been observed between ADA2p and both GCN5p and the carboxyl-terminal 250 amino acids of NGG1p (13, 16). Based on the finding that single and double disruptions of ngg1 and ada2 have similar effects on inhibition of GAL4p and PDR1p, we suggested that the same or related ADA complexes are involved in transcriptional activation and repression (9, 18). Other coactivator complexes also appear to be involved in the positive and negative regulation of transcription. The RNA polymerase II holoenzyme contains components (SIN4p, RGR1p, and ROX3p) that are required for transcriptional repression (19, 20).
The ADA proteins were predicted to interact with the basal transcriptional machinery and perhaps act as a regulatory bridge between activators and this machinery (11). An interaction between the ADA complex and TBP has been demonstrated by affinity chromatography (21). Recent genetic experiments showing that mutations in the gene encoding TBP (SPT15) have partial resistance to overexpression of GAL4p-VP16 (the ADA phenotype) also support a link between the ADA proteins and TBP (17). However, the component(s) of the complex required for the interaction with TBP is unknown. Components of the ADA complex have also been found to interact with activator proteins. PDR1p interacts with the amino-terminal 373 amino acids of NGG1p in a two-hybrid analysis and by coimmunoprecipitation (9). ADA2p in yeast extracts associates with the activation domains of VP16, GCN4p, and GAL4p on affinity columns (21-23). The ability of recombinant ADA2p to interact with VP16 in vitro suggests that ADA2p may have a principal role in these interactions (21), although disruption of ADA2 did not totally abolish the two-hybrid interaction between NGG1p and PDR1p (9).
To determine the functional associations of NGG1p and ADA2p that occur in vivo, we have begun a biochemical analysis of these proteins using epitope-tagged derivatives. We have found that virtually all of cellular ADA2p is associated with NGG1p in multiple high molecular mass complexes. In addition, we have found that TBP coimmunoprecipitates with NGG1p. The significance of the interaction with TBP is suggested by the fact that deletion of amino acids 274-307 of NGG1p, which results in the slow growth phenotype and loss in repression of GAL4p seen in a ngg1 disruption (18), also results in loss of association with TBP.
DNA Constructs
To epitope tag NGG1p, a NotI restriction site was
introduced into YCplac33-NGG1 directly upstream of the TAA
stop codon (8). An oligonucleotide encoding a triple hemagglutinin (HA)
epitope (kindly provided by M. Manolson) was cloned into this site.
YIplac211-HA-NGG1 was constructed by ligating a 2.7-kilobase
pair SstI-PstI fragment from this allele
(including the NGG1p coding region) with an
EcoRI-SstI fragment that contains 2.3 kilobase
pairs of sequence upstream of NGG1 into the EcoRI
and PstI sites of YIplac211 (24).
YIplac211-HA-ngg1274-307 was constructed
from YIplac211-HA-NGG1 by digestion of the internal BglII sites and religation. YCp88-HA-ADA2 was
constructed using the identical strategy. The coding region was flanked
by HindIII and SstI restriction sites and cloned
into the equivalent sites of the URA3 centromeric plasmid
YCp88 (25) to allow expression of tagged ADA2 from a
DED1 promoter.
Yeast Strains, Media, and Growth Conditions
Yeast strain CY756 (8) is a derivative of KY320 (26) that
contains a TRP1 disruption of ngg1 (Table
I). YIplac211-HA-NGG1 and
YIplac211-HA-ngg1274-307 were digested with
KpnI and integrated into CY756 by selecting for
Ura+ colonies to generate SY6-2 and SY7-3,
respectively. CY914 is isogenic to CY756, but contains a Tn10 LUK
disruption of the GAL80 coding region (8).
Ura+ colonies were selected and verified for
disruption by Southern blotting and then selected for loss of
URA3 on 5-fluoroorotic acid (27). CY946 is a derivative of
CY914 that contains a Tn10 LUK disruption of the ADA2 coding
region (kindly provided by J. Horiuchi and L. Guarente) (10). CY947 and
CY1077 are derivatives of CY946 and CY914, respectively, that contain
Myc-tagged NGG1 expressed from the DED1 promoter
integrated at his3 (18).
|
Yeast strains were grown at 30 °C in YPD broth (1% yeast extract, 2% peptone, 2% glucose) or in minimal medium (0.67% yeast nitrogen base without amino acids, 2% glucose and supplemented with amino acids as required).
Nuclear Extracts
Nuclei were prepared as described by Ponticelli and Struhl (28) and then disrupted for SDS-PAGE by addition of SDS to a concentration of 2% and incubation at 70 °C for 10 min. Insoluble material was removed by centrifugation at 35,000 × g for 10 min.
Preparation of Whole Cell Extract
Yeast whole cell extract was prepared as described by Schultz et al. (29) with minor modifications. Cells were grown in YPD broth to A600 = 1.5-2.0 and pelleted, and wet weight was determined. Cells were washed successively in water (4 volumes/g), extraction buffer (2 volumes/g), and extraction buffer containing protease inhibitors (1.2 volumes/g; 0.2 mM phenylmethylsulfonyl fluoride, 0.1 mM benzamidine hydrochloride, 2 µg/ml pepstatin A, 2 µg/ml leupeptin, 3 µg/ml aprotinin, 0.1 mg/ml trypsin inhibitor). The paste from the pelleted cells was extruded from a syringe into liquid nitrogen. Frozen cells were broken under liquid nitrogen with a ceramic mortar and pestle. 0.6 volumes of extraction buffer was added to the powder of broken cells. The suspension was cleared by centrifugation at 40,000 × g for 1 h. Protamine sulfate was added to a final concentration of 0.2% to the supernatant (30). The extract was cleared by centrifugation at 27,000 × g for 15 min, and the protein concentration of the supernatant was standardized to 40 mg/ml (31).
Fractionation of NGG1p and ADA2p
Ion-exchange Chromatography200 mg of a mixture of whole cell extract from yeast strains SY6-2 and CY947 containing YCp88-HA-ADA2, prepared in 40 mM Tris-HCl (pH 7.7), 20 mM NaCl, 0.1% Nonidet P-40, and 10% glycerol, was applied to a Q-Sepharose Fast Flow (Fast Q) HR10/10 column (Pharmacia Biotech Inc.) at a flow rate of 1.5 ml/min. After washing with 10 ml of buffer, protein was eluted with a 65-ml gradient of 20-500 mM NaCl. Protein from 200-µl aliquots of 1.5-ml fractions was precipitated with trichloroacetic acid and separated by SDS-PAGE.
Gel-filtration Chromatography16 mg of a mixture of whole cell extract from yeast strains SY6-2 and CY947 containing YCp88-HA-ADA2, prepared in 40 mM Tris-HCl (pH 7.7), 300 mM NaCl, 0.1% Nonidet P-40, and 10% glycerol, was filtered through a 0.22-µm membrane and applied at a flow rate of 0.2 ml/min to a Superose 6 HR10/30 column (FPLC, Pharmacia Biotech Inc.). Protein from 200-µl aliquots of 600-µl fractions was precipitated with 10% trichloroacetic acid, solubilized in SDS sample buffer, and separated on a 7.5% SDS-polyacrylamide gel. Similarly, 120 mg of whole cell extract from strains expressing HA-NGG1p and HA-ADA2p was prepared in 40 mM HEPES (pH 7.4), 150 mM NaCl, 0.1% Tween 20, 10% glycerol, 1 mM EDTA, and 1 mM dithiothreitol in the presence of the protease inhibitors and fractionated on a 100-ml open column of Sephacryl S-500 HR (Pharmacia Biotech Inc.) at a flow rate of 0.2 ml/min. 200-µl aliquots of alternate 1.6-ml fractions were precipitated in the presence of 10% trichloroacetic acid, separated by SDS-PAGE, and assayed for the presence of HA-ADA2p and HA-NGG1p by immunoblotting with anti-HA antibody.
To chromatograph NGG1p- and ADA2p-containing Fast Q peak fractions on Superose 6, fractions 2-5 (50 mM NaCl eluting peak) and fractions 9-12 (100 mM NaCl eluting peak) were concentrated to 200 µl using a Centricon 30 concentrator and then diluted to 500 µl with 40 mM Tris-HCl (pH 7.7), 300 mM NaCl, 0.1% Nonidet P-40, and 10% glycerol. Fractions 20-24 (250 mM NaCl eluting peak) were concentrated to 500 µl. Fractions 35-39 (450 mM NaCl eluting peak) were concentrated to 200 µl and then diluted with 40 mM Tris-HCl (pH 7.7), 100 mM NaCl, 0.1% Nonidet P-40, and 10% glycerol. Individually, the concentrated samples were fractionated on a Superose 6 column as described above. 600-µl aliquots of alternate fractions were precipitated by 10% trichloroacetic acid, separated by SDS-PAGE, and assayed for the presence of HA-NGG1p by immunoblotting with anti-HA antibody.
Immunoprecipitation of NGG1p and ADA2p Complexes
For immunoprecipitation of Myc-NGG1p with HA-ADA2p, whole cell extracts were prepared from yeast strains CY947 containing YCp88-HA-ADA2, CY946 containing YCp88-HA-ADA2, and CY1077 in 50 mM HEPES (pH 7.4), 150 mM NaCl, 16 mM magnesium acetate, 1 mM EGTA, 0.1% Nonidet P-40, 0.5 mM dithiothreitol, 10% glycerol, and protease inhibitors (immunoprecipitation buffer). 50 mg of extract was rotated for 1 h at 4 °C with 0.5 ml of Sepharose CL-4B (Pharmacia Biotech Inc.). Unbound protein was incubated with 4 µg of monoclonal antibody 12CA5 (Boehringer Mannheim) directed against the HA epitope and rotated at 4 °C for 1 h. The mixtures were added to 50 µl of protein A-Sepharose beads (Pharmacia Biotech Inc.), equilibrated in immunoprecipitation buffer, and rotated for 4 h at 4 °C. The beads were washed five times with 1.5 ml of immunoprecipitation buffer, and bound protein was eluted by incubation at 95 °C for 2 min in SDS gel loading buffer. A similar procedure was used for the immunoprecipitation of Myc-NGG1p from these extracts with the exception that the equivalent of 50 µl of ascites fluid derived from the Myc1-9E10 cell line (32) was coupled to cyanogen bromide-activated Sepharose (Pharmacia Biotech Inc.). For analysis of TBP in the complexes, whole cell extracts were prepared in SY6-2, SY7-3, and KY320. Immunoprecipitations were performed with 200 mg of extract using monoclonal anti-HA antibody covalently bound to N-hydroxysuccinimide-activated Sepharose (Berkeley Antibody). Protein was eluted from the beads by incubation at 40 °C in 4.0 M urea.
Western Blotting
Western blotting with a primary antibody from ascites fluid derived from the Myc1-9E10 cell line using polyvinylidene difluoride membrane and the SuperSignal chemiluminescence kit (Pierce) has been described (18). Probing with monoclonal anti-HA antibody, TBP polyclonal antibody (Upstate Biotechnology, Inc.), and a monoclonal antibody to the carboxyl-terminal domain of RNA polymerase II (kindly supplied by J. Ingles) (34) was performed with dilutions of primary antibody of 1:4000, 1:2000, and 1:3000, respectively.
When expressed in vitro, NGG1p interacts with ADA2p (13). Genetic experiments including the similar slow growth phenotype and relief of inhibition on GAL4p shown by single and double mutants also suggest that NGG1p and ADA2p act in a complex (13, 18). To address whether these proteins associate in vivo, we determined whether they can be coimmunoprecipitated from a yeast whole cell extract.
Epitope-tagged derivatives were constructed to immunoprecipitate and
identify NGG1p and ADA2p. NGG1p tagged with a Myc epitope at its amino
terminus is functional (18). ADA2p was tagged at its carboxyl terminus
with a HA epitope (35, 36). This derivative was also functional as
determined by its ability to complement ada2 disruptions in
restoring wild-type growth rates and repression of GAL4p (data not
shown). HA-ADA2 expressed from the DED1 promoter was introduced into yeast strains CY947 (myc-NGG1 ada2) and
CY946 (ngg1::TRP1 ada2) on a URA3
centromeric plasmid (YCp88-HA-ADA2). Whole cell extracts
were prepared from these strains and from CY1077 (myc-NGG1
ADA2). The extracts containing HA-ADA2p were treated with anti-HA
antibody, separated by SDS-PAGE, and Western-blotted with anti-Myc
antibody to detect Myc-NGG1p (Fig. 1A). The
presence of Myc-NGG1p in immunoprecipitates with HA-ADA2p (lane
1) shows that NGG1p and ADA2p expressed in vivo are
associated. The specificity of the association was shown by the absence
of a band of ~116 kDa that reacts with anti-Myc antibody in
immunoprecipitates from strains lacking HA-ADA2p (lane 3) or
Myc-NGG1p (lane 2).
To determine the relative amount of ADA2p associated with NGG1p, we performed an immunodepletion experiment. 600 µg of whole cell extract containing Myc-NGG1p and HA-ADA2p (CY947 containing YCp88-HA-ADA2) was incubated with anti-Myc antibody coupled to cyanogen bromide-activated Sepharose 4B or to Sepharose 4B alone. The amount of HA-ADA2p bound to the beads and thus associated with Myc-NGG1p and that found independent of Myc-NGG1p were determined by Western blotting with anti-HA antibody (Fig. 1B). As in the reciprocal experiment shown in Fig. 1A, HA-ADA2p coimmunoprecipitated with Myc-NGG1p (lane 1). In fact, <2% of HA-ADA2p was found in the immune supernatant, not complexed with Myc-NGG1p (compare lanes 1 and 2). The specificity of the coimmunoprecipitation of HA-ADA2p was confirmed by the absence of HA-ADA2p bound to the control Sepharose 4B beads (compare lanes 3 and 4).
NGG1p and ADA2p Cofractionate on Ion-exchange and Gel-filtration ColumnsTo further examine the interaction between NGG1p and
ADA2p, we determined their elution profiles after fractionation of
whole cell extracts by ion-exchange chromatography (Fig.
2). To enable detection of both proteins on the same
Western blot, we constructed a derivative of NGG1p with a
carboxyl-terminal HA tag. HA-NGG1p was functional as determined by its
ability to complement ngg1::TRP1 (data not shown).
200 mg of whole cell extract was applied to a FPLC Fast Q column in
buffer containing 20 mM NaCl and eluted in a linear
gradient of 20-500 mM NaCl. Equal volumes of alternate fractions were examined by SDS-PAGE, and the presence of ADA2p and
NGG1p was detected by Western blotting with anti-HA antibody (Fig.
2A). Densitometric scanning revealed that NGG1p eluted in four peaks centered at fractions 4 (~50 mM NaCl), 10 (100 mM NaCl), 22 (250 mM NaCl), and 36 (450 mM NaCl) (Fig. 2B). ADA2p cofractionated with
NGG1p, with the exception of the 450 mM NaCl eluting
fraction. Individually, the 50, 100, and 250 mM NaCl
complexes were reapplied to the Fast Q column to ensure that they were
chromatographing true. Each NGG1p-containing complex eluted in a single
peak at the same position as it had first chromatographed (data not
shown). The occurrence of three separable fractions containing both
NGG1p and ADA2p suggests that they are associated and found within
multiple complexes.
To provide additional support for the association of ADA2p and NGG1p in
multiple complexes and to obtain approximate sizes of these complexes,
the elution profiles of the tagged derivatives were examined after
separation of whole cell extract on gel-filtration columns. Extract
containing HA-ADA2p and HA-NGG1p was fractionated on a Superose 6 column in 300 mM NaCl (Fig. 3A).
Equal volumes of alternate fractions were examined by SDS-PAGE, and the
presence of ADA2p and NGG1p was detected by Western blotting with
anti-HA antibody. NGG1p eluted in three peaks centered at fractions 14, 34, and 40. By comparison with protein standards, these fractions correspond to apparent molecular sizes of ~1.5 MDa (this value was
obtained by linear extrapolation from the calibration proteins and is
an underestimate of its size; see below), 200 kDa, and 90 kDa,
respectively. Approximately 5% of NGG1p fractionated at a size
indicative of a monomer (90-kDa peak); the amount of this form varied
from <3 to 12% in four independent experiments. HA-ADA2p had a
virtually identical elution profile to HA-NGG1p, lacking only the peak
at fraction 40 and having a slightly more prominent shoulder at
fraction 20. A peak corresponding to monomeric ADA2p was not
apparent.
ADA2p and NGG1p coelute on a Superose 6 gel-filtration column. A, densitometric scanning profiles of
immunoblots of ADA2p and NGG1p obtained after fractionation of yeast whole cell extract on a Superose 6 column. 16 mg of whole cell extract from strains expressing HA-NGG1p and HA-ADA2p was fractionated on Superose 6. Equal volumes of alternate fractions were separated by SDS-PAGE and
assayed for the presence of HA-ADA2p and HA-NGG1p by immunoblotting with anti-HA antibody. The dashed line represents NGG1p; the
solid line represents ADA2p. The void volume was determined
with high molecular mass DNA and occurs at fraction 10. Arrowheads depict the peak fractions containing the
following calibration proteins: thyroglobulin (669 kDa), apoferritin
(443 kDa), -amylase (200 kDa), and bovine serum albumin (66 kDa).
Note that the scale for ADA2p has been magnified 2-fold in this graph
as compared with Fig. 2. B, densitometric scanning profiles
of immunoblots of NGG1p obtained after fractionation of the NGG1p- and
ADA2p-containing Fast Q peak fractions on a Superose 6 column. Fast Q
fractions 2-5 (50 mM NaCl eluting peak), fractions 9-12
(100 mM NaCl eluting peak), fractions 20-24 (250 mM NaCl eluting peak), and fractions 35-39 (450 mM NaCl eluting peak) were concentrated using a Centricon 30 concentrator and then diluted in extraction buffer to a final concentration of ~300 mM NaCl and a volume of 500 µl.
Individually, the concentrated samples were fractionated on Superose 6 as described above. Equal volumes of alternate fractions were
precipitated, separated by SDS-PAGE, and assayed for the presence of
HA-NGG1p by immunoblotting with anti-HA antibody. The void volume was
determined with high molecular mass DNA and occurs at fraction 10. Arrowheads depict the peak fractions containing the
calibration proteins with the sizes (kDa) indicated.
To determine the relationship between the putative complexes identified by ion-exchange and gel-filtration chromatography, the Fast Q peak fractions were fractionated on Superose 6 (Fig. 3B). The 50 and 100 mM NaCl eluting fractions from the Fast Q column had apparent sizes of ~1.5 MDa. The 250 mM NaCl fraction was resolved into two complexes containing NGG1p with approximate sizes of 900 and 200 kDa. The 900-kDa peak may represent the shoulder at fraction 20 seen when whole cell extract was fractionated on Superose 6 (see below). The 450 mM NaCl fraction from the Fast Q column contained the 90-kDa form of NGG1p. The combination of gel-filtration and ion-exchange chromatography allowed us to identify four complexes containing both ADA2p and NGG1p, two with apparent molecular masses of ~1.5 MDa and individual complexes of ~900 and 200 kDa.
To ensure that the high molecular mass ADA complex did not result from
the formation of nonspecific aggregates that fractionate near the void
volume of the Superose 6 column, we analyzed the elution profile of
ADA2p and NGG1p after separation on Sephacryl S-500 HR (Fig.
4). The void volume was determined with high molecular mass DNA, and the column was calibrated with blue dextran 2000 (Pharmacia Biotech Inc.), thyroglobulin (669 kDa), and -amylase (200 kDa). Three peak fractions containing NGG1p and ADA2p were observed,
corresponding to the 1.5-MDa, 900-kDa, and 200-kDa complexes seen on
the Superose 6 column. The 900-kDa complex was resolved from the larger
complexes after chromatography on Sephacryl S-500. The high molecular
mass complexes were not excluded from the Sephacryl S-500 column and
eluted one fraction before blue dextran 2000. Considering the general
differences in fractionation of dextrans and globular proteins by gel
filtration, this suggests that these complexes have predicted sizes of
>2.0 MDa.
Stability of NGG1p and ADA2p Is Co-dependent
The
integrity of a protein complex is often critical for the stability of
its component members. To determine if the stability of ADA2p was
dependent on NGG1p, we expressed HA-ADA2 from the constitutive DED1 promoter (37) in yeast strains containing (CY947) or not containing (CY946) NGG1. The DED1
promoter is not influenced by NGG1, allowing an analysis of
protein stability (18). The presence of HA-ADA2p was detected by
Western blotting with anti-HA antibody (Fig.
5A). Almost no full-length ADA2p was found in
CY946. To further support that NGG1p regulates the stability of ADA2p
rather than its expression, we have observed a band of ~10 kDa
reacting with anti-HA antibody in the CY946 extract, indicative of a
proteolytic fragment of HA-ADA2p (data not shown). We conclude that the
stability of ADA2p is highly dependent on NGG1p.
The reciprocal experiment was performed in which Myc-NGG1p was expressed in strains containing or not containing ADA2p. Myc-NGG1p was detected by Western blotting with anti-Myc antibody. As shown in Fig. 5B, little or no NGG1p was detectable in the strain lacking ADA2p, even when 300 µg of total protein was analyzed. The dependence of the stability of ADA2p and NGG1p on the presence of each other again supports their association in vivo.
NGG1p Is a Nuclear ProteinThe action of NGG1p as a
transcriptional coactivator/repressor predicts that it should be found
in the nucleus. ADA2p has been found in nuclear extracts (21); however,
cytoplasmic extracts were not examined. Furthermore, ADA2p-independent
NGG1p might potentially be involved in a cytoplasmic process. To
determine the cellular localization of NGG1p, nuclear and cytoplasmic
fractions were prepared from a yeast strain expressing HA-NGG1p and
analyzed by Western blotting with anti-HA antibody (Fig.
6A). The integrity of the fractions was
examined by reprobing the filter with antibody to the carboxyl-terminal
domain of the large subunit of RNA polymerase II (Fig. 6B).
Like RNA polymerase II, HA-NGG1p was almost exclusively found in the
nuclear fraction. On extensive overloading, trace amounts of HA-NGG1p
could be detected in the cytoplasmic fraction.
Amino Acids 274-307 of NGG1p Are Required for Interaction with TBP
Barlev et al. (21) have found that ADA2p contained
in nuclear extracts will associate with TBP. Their inability to find a
direct interaction for recombinant proteins suggests that the interaction between TBP and ADA2p is indirect. A possible role for
NGG1p in the interaction is supported by the finding that amino acids
1-308 of NGG1p, when fused to a GAL4p DNA-binding domain, will
activate transcription independently from ADA2p (18). This activation
requires amino acids 274-307 of NGG1p. To test for the involvement of
NGG1p in the association of an ADA complex with TBP, we
immunoprecipitated HA-NGG1p and HA-NGG1p274-307 from
whole cell extracts with anti-HA antibody and probed for TBP by Western
blotting (Fig. 7A). TBP coimmunoprecipitated
with HA-NGG1p (compare lanes 1 and 3). TBP was
not found in the immunoprecipitate from the
HA-NGG1p
274-307 extract (lane 2); therefore, amino acids 274-307 of NGG1p are essential for interaction of an ADA
complex with TBP.
Although the expression of NGG1p274-307 is comparable
to the full-length protein (18), the inability of TBP to coimmunoprecipitate with HA-NGG1p
274-307 could be
indirect, resulting from the lack of association of
NGG1p
274-307 with an ADA complex. Therefore, we
analyzed for complex formation by HA-NGG1p
274-307 by
determining its elution profile from a Superose 6 column.
HA-NGG1p
274-307 was found in complexes of ~900 and
200 kDa (data not shown). The largest complex containing the deletion
derivative eluted approximately four fractions later than that for the
wild-type protein, suggesting that amino acids 274-307 are required
for protein-protein contacts necessary in the formation of the largest
ADA complexes.
We compared the elution profile of TBP with NGG1p from the Fast Q ion-exchange column as a first step in determining which of the NGG1p- and ADA2p-containing complexes associate with TBP (Fig. 7B). TBP was found in two peaks centered at fractions 4 and 22. The profile of TBP from the Fast Q column paralleled the elution of NGG1p found within one of the two 2-MDa complexes and that contained within the 900/200-kDa peak. Since TBP immunoprecipitates with ADA2p (Fig. 7A), this result indicates that TBP is associated with at least one of these complexes. Furthermore, the absence of TBP in the NGG1p peaks at fractions 12 and 36 indicates that TBP is not associated with one of the two largest ADA complexes or with free NGG1p.
Previous reports on components of the ADA complex demonstrated that ADA2p, NGG1p, GCN5p, and ADA5p associate in vitro and by two-hybrid analysis (12, 13, 16, 17). The similar effects of single and double disruptions of ngg1, ada2, and gcn5 on transcriptional activation and repression have been used to support the functional association of the proteins in vivo (10, 12, 13, 18). The finding of Candau et al. (16) that the stability of ADA2p is dependent on GCN5 and our finding that the stability of ADA2p and NGG1p depends on the presence of each other provide additional evidence for their association in vivo. However, the instability of the proteins does limit the interpretation of previous gene disruption experiments. In this report, we provide biochemical evidence for the functional association of ADA2p and NGG1p. The association of NGG1p and ADA2p was revealed by their coimmunoprecipitation from yeast whole cell extracts. This was supported by the coelution of the proteins in multiple peaks after fractionation on both gel-filtration and ion-exchange columns. It should also be noted that Candau and Berger (38) have shown that the stability of LexA-ADA2p is dependent on the presence of NGG1p and that NGG1p and GCN5p coimmunoprecipitate with epitope-tagged ADA2p when the three proteins are overexpressed in vivo.
The combination of gel-filtration and ion-exchange chromatography resolved four complexes containing both ADA2p and NGG1p (ADA complexes). Two of these had estimated sizes of ~2 MDa; the other two were ~200 and 900 kDa. The simplest explanation for the 200-kDa complex is that it represents a minimum complex containing ADA2p, NGG1p, and perhaps GCN5p. The presence of GCN5p would be consistent with the demonstrated interaction with ADA2p in vitro (13) and its stabilization of LexA-ADA2p (38).
The 2-MDa complexes and the 900-kDa ADA complex from the gel-filtration chromatography almost certainly contain additional NGG1p- and ADA2p-associated proteins. We do not believe that the high molecular mass ADA complexes arise as the result of the interaction of the 200-kDa complex with DNA. This possibility was suggested by the finding that the Swi·Snf complex interacts with DNA (39). First, the yeast whole cell extract used for the chromatography experiments was treated with protamine sulfate to remove DNA. Second, ADA complexes fractionated on the Fast Q column were subsequently chromatographed on Superose 6 and shown to have approximate sizes of >1.5 MDa, 900 kDa, and 200 kDa. These complexes are almost certainly free of DNA since any residual DNA not removed by protamine sulfate treatment would be retained at low salt concentrations on the cation-exchange column. Third, we have found the same elution profile on Superose 6 when the extract is chromatographed in the presence of ethidium bromide.2
There are several potential reasons for the presence of four biochemically resolvable complexes containing ADA2p and NGG1p. Activation and repression may require complexes with different components. Stable subcomplexes (for example, the 200-kDa complex) may represent a core that is an intermediate in the formation of these forms rather than having an independent functional role. NGG1p and ADA2p may also function as components of non-ADA complexes. The finding of TBP in immunoprecipitates with NGG1p might suggest that one of the complexes is a TBP·TBP-associated factor complex; however, the sizes of proteins that coimmunoprecipitate with NGG1p do not resemble the sizes of the yeast TBP-associated factors (40, 41).2 The finding that ADA5p/SPT20p may associate with NGG1p/ADA3p (17) suggests that some of these complexes may contain the genetically related proteins SPT3, SPT7, and SPT8 (17, 42). While we cannot exclude the possibility that the smaller complexes dissociate from the larger complexes during the isolation procedure, independently, Cote et al.3 have found similar chromatographically distinct, high molecular mass complexes containing GCN5p and ADA2p. In addition, the high molecular mass complexes did not dissociate after a second chromatography step on either Superose 6 or Fast Q columns.
Amino Acids 274-307 of NGG1p Are Required for Interaction with TBPAs coactivators, the ADA proteins were predicted to provide a regulatory link between the basal transcriptional machinery and activator proteins. Interactions between activators including GCN4p, VP16, GAL4p, and PDR1p with components of the ADA complex(es) have been observed by affinity chromatography, coimmunoprecipitation, and two-hybrid analysis (9, 21-23). A link between the ADA complex(es) and the basal machinery was established with the finding that ADA2p in nuclear extracts associated with a GST-TBP fusion protein on an affinity column (21) and is supported by the genetic findings that ADA5/SPT20 encodes a protein functionally related to TBP (17, 42). The inability of Barlev et al. (21) to detect an interaction between TBP and recombinant ADA2p suggested that the association might be mediated by another component of the ADA complex(es). Our finding of TBP in immunoprecipitates with NGG1p demonstrates in vivo the interaction between the ADA complex(es) and TBP that was found by affinity chromatography. Furthermore, we have shown that the association with TBP requires amino acids 274-307 of NGG1p. The role of NGG1p in the interaction with TBP is likely indirect since TBP was not found associated with monomeric NGG1p. This result, along with the finding that recombinant ADA2p does not interact with TBP (21) and the identification of GCN5p as a histone acetyltransferase (43), suggests that none of these three ADA components interacts directly with TBP.
The requirement for amino acids 274-307 of NGG1p for association with
TBP agrees with the region being crucial for function of the molecule.
Deletion of this region results in a loss of repression of GAL4p and in
the slow growth phenotype typical of disruption of ngg1
(18). Amino acids 1-308 of NGG1p activate transcription as a GAL4p
fusion independent of ADA2p (18). This activation depends on amino
acids 274-307 (18). Mutations can be isolated in this region that
either stimulate or inhibit the action of NGG1p in repression of GAL4p
and the activity of GAL4p-NGG1p fusions in transcriptional activation
(18). Interestingly, this region contains a Phe-rich segment with
homology to a group of proteins including human immunodeficiency virus
group-specific antigen protein that strongly predicts to be an
amphipathic -helix (10, 18). An involvement of amino acids 274-307
in protein-protein interactions is also suggested by the finding that
this region is required for a two-hybrid interaction with PDR1p
(9).
NGG1p, ADA2p, and likely other components of the ADA complex(es) fit into a class of regulators that are able to stimulate or repress activator function. The link between activation and repression for NGG1p is particularly strong since a region essential for repression (amino acids 274-307) is also required for transcriptional activation as a GAL4p-NGG1p fusion (18) and for association with TBP. Mechanisms for activation and repression may be closely related. An activator protein may signal an ADA complex to either stimulate or repress the activities of TBP. Differences leading to activation or repression could arise because specific activators elicit different conformational changes in the complex, perhaps by targeting different components or possibly by acting on different ADA complexes. The finding by Brownell et al. (43) that GCN5p is a histone acetyltransferase also suggests that some of the activities of the complex may be mediated by chromatin modification, with others being dependent on interaction with the basal transcriptional machinery.
Other dual function regulators probably function to stimulate or inhibit the basal transcriptional machinery. PAF1p was isolated as a RNA polymerase II-associated protein that differentially activates or represses transcription (44). Recently, SIN4p, ROX3p, and RGR1p, which had previously been characterized with roles in activation and repression, were found as components of the RNA polymerase II holoenzyme (19, 20).
We thank Drs. Jim Ingles and Michael Schultz for kindly providing antibodies, Jacques Cote and Jerry Workman for communicating unpublished results, Morris Manolson for plasmids, and Anne Brickendon for the preparation of the Myc ascites fluid. We are also grateful to Joe Martens, Julie Genereaux, Bri Lavoie, Eric Ball, Mark Watson, Stan Dunn, and George Chaconas for useful comments on this manuscript.